Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Naoki Okamura BSc | President, CEO & Director | 1.73M | -- | 1962 |
| Mr. Atsushi Kitamura | Senior Executive Officer & CFO | -- | -- | -- |
| Nobue Yasuda | General Manager of Finance & Accounting Department | -- | -- | -- |
| Mr. Yoshitsugu Shitaka Ph.D. | Chief Scientific Officer & Senior Managing Executive Officer | -- | -- | -- |
| Ms. Tatjana Dragovic J.D. | General Counsel, Chief Ethics & Compliance Officer | -- | -- | -- |
| Mr. Katsuyoshi Sugita | Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director | -- | -- | 1967 |
| Mr. Stig Ogata | Vice President of Corporate Communications | -- | -- | -- |
| Mr. Nobuaki Tanaka | President of Japan Commercial & Senior Corporate Executive | -- | -- | -- |
| Jun Kono | Senior Executive Officer & Head of Japan Commercial | -- | -- | -- |
| Ms. Leticia Delgado-Herrera | VP and Rx+ M&D Head | -- | -- | -- |
Astellas Pharma Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 14,754
Description
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. Astellas Pharma Inc. was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Corporate Governance
Upcoming Events
April 25, 2025 at 6:00 AM UTC
Astellas Pharma Inc. Earnings Date
Recent Events
March 28, 2025 at 12:00 AM UTC
Ex-Dividend Date